Micropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic

Glaucoma is the leading cause of irreversible blindness worldwide, with primary open angle glaucoma (POAG) accounting for the greatest number of total glaucoma cases. This study aimed to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) as a primary procedu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hsiao-Ling Chang, Shih-Chun Chao, Ming-Tsung Lee, Hung-Yu Lin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	micropulse transscleral cyclophotocoagulation diode laser glaucoma intraocular pressure Medicine R
Acceso en línea:	https://doaj.org/article/e3b9b8551892478fb3ba86c7d30f5066
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e3b9b8551892478fb3ba86c7d30f5066
record_format	dspace
spelling	oai:doaj.org-article:e3b9b8551892478fb3ba86c7d30f50662021-11-25T17:46:20ZMicropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic10.3390/healthcare91115632227-9032https://doaj.org/article/e3b9b8551892478fb3ba86c7d30f50662021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9032/9/11/1563https://doaj.org/toc/2227-9032Glaucoma is the leading cause of irreversible blindness worldwide, with primary open angle glaucoma (POAG) accounting for the greatest number of total glaucoma cases. This study aimed to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) as a primary procedure in POAG during the COVID-19 pandemic. We retrospectively analyzed 60 eyes of 52 patients, who were diagnosed with mild-to-end-stage POAG without previous glaucoma surgery and received MP-TSCPC between 1 January 2020 and 31 August 2020. The mean preoperative intraocular pressure (IOP) significantly decreased from 27.8 mm Hg to 19.8, 20.1, 20.3, 20.4, and 20.2 mm Hg at 1, 3, 6, 9, and 12 months, respectively (all <i>p</i> < 0.05). The mean number of IOP-lowering medications used significantly decreased from 3.3 at the baseline to 1.6, 1.8, 1.8, 1.9, and 1.9 at 1, 3, 6, 9, and 12 months, respectively (all <i>p</i> < 0.001). Total withdrawal of antiglaucoma medications was fulfilled in five patients. The main outcome was achieved in 81.7% at postoperative month 12. The most common adverse effect was transient mydriasis (28.3%). No major complications were encountered. MP-TSCPC seems to be an effective and safe treatment to reduce IOP and the medication burden with minimal vision-threatening complications in mild-to-end-stage POAG patients without previous glaucoma surgery.Hsiao-Ling ChangShih-Chun ChaoMing-Tsung LeeHung-Yu LinMDPI AGarticlemicropulsetransscleral cyclophotocoagulationdiode laserglaucomaintraocular pressureMedicineRENHealthcare, Vol 9, Iss 1563, p 1563 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	micropulse transscleral cyclophotocoagulation diode laser glaucoma intraocular pressure Medicine R
spellingShingle	micropulse transscleral cyclophotocoagulation diode laser glaucoma intraocular pressure Medicine R Hsiao-Ling Chang Shih-Chun Chao Ming-Tsung Lee Hung-Yu Lin Micropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic
description	Glaucoma is the leading cause of irreversible blindness worldwide, with primary open angle glaucoma (POAG) accounting for the greatest number of total glaucoma cases. This study aimed to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) as a primary procedure in POAG during the COVID-19 pandemic. We retrospectively analyzed 60 eyes of 52 patients, who were diagnosed with mild-to-end-stage POAG without previous glaucoma surgery and received MP-TSCPC between 1 January 2020 and 31 August 2020. The mean preoperative intraocular pressure (IOP) significantly decreased from 27.8 mm Hg to 19.8, 20.1, 20.3, 20.4, and 20.2 mm Hg at 1, 3, 6, 9, and 12 months, respectively (all <i>p</i> < 0.05). The mean number of IOP-lowering medications used significantly decreased from 3.3 at the baseline to 1.6, 1.8, 1.8, 1.9, and 1.9 at 1, 3, 6, 9, and 12 months, respectively (all <i>p</i> < 0.001). Total withdrawal of antiglaucoma medications was fulfilled in five patients. The main outcome was achieved in 81.7% at postoperative month 12. The most common adverse effect was transient mydriasis (28.3%). No major complications were encountered. MP-TSCPC seems to be an effective and safe treatment to reduce IOP and the medication burden with minimal vision-threatening complications in mild-to-end-stage POAG patients without previous glaucoma surgery.
format	article
author	Hsiao-Ling Chang Shih-Chun Chao Ming-Tsung Lee Hung-Yu Lin
author_facet	Hsiao-Ling Chang Shih-Chun Chao Ming-Tsung Lee Hung-Yu Lin
author_sort	Hsiao-Ling Chang
title	Micropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic
title_short	Micropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic
title_full	Micropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic
title_fullStr	Micropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic
title_full_unstemmed	Micropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic
title_sort	micropulse transscleral cyclophotocoagulation as primary surgical treatment for primary open angle glaucoma in taiwan during the covid-19 pandemic
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e3b9b8551892478fb3ba86c7d30f5066
work_keys_str_mv	AT hsiaolingchang micropulsetransscleralcyclophotocoagulationasprimarysurgicaltreatmentforprimaryopenangleglaucomaintaiwanduringthecovid19pandemic AT shihchunchao micropulsetransscleralcyclophotocoagulationasprimarysurgicaltreatmentforprimaryopenangleglaucomaintaiwanduringthecovid19pandemic AT mingtsunglee micropulsetransscleralcyclophotocoagulationasprimarysurgicaltreatmentforprimaryopenangleglaucomaintaiwanduringthecovid19pandemic AT hungyulin micropulsetransscleralcyclophotocoagulationasprimarysurgicaltreatmentforprimaryopenangleglaucomaintaiwanduringthecovid19pandemic
_version_	1718412078778155008

Micropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic

Ejemplares similares